Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Clinical trials frequently include multiple end points that ...

Please provide your email address to receive an email when new articles are posted on . Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection ...

Please provide your email address to receive an email when new articles are posted on . First phase 3 study to show a survival benefit with adjuvant therapy in kidney cancer. Adjuvant pembrolizumab ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab Cohort 3 included 41 ...

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

A combination of belzutifan, pembrolizumab, and lenvatinib showed encouraging results as first-line treatment for advanced RCC in an early phase trial. Phase 3 trial data are pending. Among first-line ...

Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug combination than with previous therapy options. Institute for Quality and Efficiency in Health Care ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Investigators analyzed the immune-modulatory cancer vaccine IO102-IO103 plus pembrolizumab for PFS in patients with untreated advanced melanoma.